تقرير
أعرض في EDS

Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.

التفاصيل البيبلوغرافية
العنوان: Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
المؤلفون: Gosser C; Internal Medicine, University of Louisville School of Medicine, Louisville, USA., Al Bawaliz A; Hematology and Medical Oncology, University of Louisville Hospital, Louisville, USA., Bahaj W; Hematology and Medical Oncology, University of Louisville Hospital, Louisville, USA., Chesney J; Hematology and Medical Oncology, University of Louisville Hospital, Louisville, USA., Ranjan S; Hematology and Medical Oncology, University of Louisville Hospital, Louisville, USA.
المصدر: Cureus [Cureus] 2023 Nov 18; Vol. 15 (11), pp. e49007. Date of Electronic Publication: 2023 Nov 18 (Print Publication: 2023).
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Immune checkpoint inhibitors (ICIs) have considerably changed the management of several malignancies. Although these agents transformed the scope of management in oncology and proved long-term efficacy, they have been associated with numerous autoimmune-related adverse events. We presented a case of a 61-year-old male with a history of non-small cell lung cancer (NSCLC) who presented with respiratory failure requiring mechanical ventilation. He was discharged with a working diagnosis of myasthenia gravis crisis secondary to the use of pembrolizumab. On further evaluation, he was found to possibly have pembrolizumab-induced myositis. He was treated with plasmapheresis, methylprednisolone, and rituximab and achieved significant improvement. Pembrolizumab, a monoclonal antibody, is an ICI that targets programmed death protein 1 (PD-1), thereby blocking the interaction between PD-1 and PDL-1, leading to an enhancement of T-cell mediated immune response against tumor cells. Pembrolizumab has been used to treat a variety of malignancies including melanoma, NSCLC, and other solid tumors. Though ICIs have revolutionized the field of oncology, they should be used with caution. ICIs can cause immune-related adverse events (irAEs), including myasthenia gravis and myositis. Diagnosing irAEs is challenging due to their nonspecific presentations and lack of antibody markers. Therefore, patients and clinicians should be aware of irAEs in order to initiate timely intervention.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Gosser et al.)
References: Sci Rep. 2017 Mar 08;7:44173. (PMID: 28272463)
Semin Arthritis Rheum. 2019 Feb;48(4):736-740. (PMID: 29909921)
Arthritis Rheumatol. 2021 May;73(5):866-874. (PMID: 33258544)
JAMA Dermatol. 2015 Nov;151(11):1206-1212. (PMID: 26222619)
J Immunol. 2008 Nov 15;181(10):6738-46. (PMID: 18981091)
Cancer Treat Rev. 2017 Jul;58:70-76. (PMID: 28689073)
Curr Rheumatol Rep. 2019 Feb 21;21(4):10. (PMID: 30790071)
Arthritis Rheum. 2009 Aug;60(8):2505-12. (PMID: 19644888)
J Exp Med. 2014 Jan 13;211(1):89-104. (PMID: 24395888)
Ann Oncol. 2020 Sep;31(9):1273-1275. (PMID: 32425357)
Rheumatology (Oxford). 2017 Jan;56(1):26-36. (PMID: 27121778)
J Formos Med Assoc. 2020 Oct;119(10):1461-1475. (PMID: 31444018)
FEBS Lett. 2014 Jan 21;588(2):368-76. (PMID: 24161671)
Ann Oncol. 2016 Jul;27(7):1352-3. (PMID: 26940685)
Eur J Cancer. 2018 Oct;102:49-51. (PMID: 30138772)
Immunol Rev. 2010 Jul;236:219-42. (PMID: 20636820)
Histopathology. 2017 Mar;70(4):558-567. (PMID: 28000302)
JAMA Neurol. 2017 Oct 1;74(10):1216-1222. (PMID: 28873125)
فهرسة مساهمة: Keywords: immune checkpoint inhibitor; myasthenia gravis; myositis; oncology; rituximab
تواريخ الأحداث: Date Created: 20231219 Latest Revision: 20231220
رمز التحديث: 20231220
مُعرف محوري في PubMed: PMC10726830
DOI: 10.7759/cureus.49007
PMID: 38111441
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.49007